Prognostic Value of the Stress Hyperglycemia Ratio for In-Hospital Mortality in Critically Ill Patients With COVID-19
The European Research Journal · 2026-12-01 · 1431-1437
DOI: 10.18621/eurj.1281 ↗Abstract
Objective: Hyperglycemia is associated with adverse outcomes in patients with COVID-19. However, the prognostic significance of chronic glycemic status, reflected by glycated hemoglobin (HbA1c), and relative hyperglycemia, assessed by the stress hyperglycemia ratio (SHR), remains unclear. This study aimed to evaluate the association of HbA1c and SHR with in-hospital mortality in critically ill patients with COVID-19. Methods: In this retrospective observational study, 324 adult patients with confirmed COVID-19 admitted to the intensive care unit were evaluated. Admission blood glucose and HbA1c levels were obtained from laboratory records. The SHR was calculated to assess relative hyperglycemia. Factors associated with in-hospital mortality were analyzed using multivariable logistic regression. Results: Of the 324 patients included in the study, 125 (38.6%) died during hospitalization. Non-survivors had a significantly higher SHR compared with survivors (median [IQR], 1.30 [0.65] vs 1.15 [0.43]; P = .003). Admission glucose levels were also higher in non-survivors (178 versus 147 mg/dL; P = .01), as was the glycemic gap (34.3 and 20.2 mg/dL, respectively; P = .008). In contrast, HbA1c levels were similar between non-survivors and survivors (median [IQR], 5.9% [2.2%] vs 5.8% [2.5%]; P = .589). In multivariable logistic regression analysis, SHR remained independently associated with mortality across all adjusted models. Receiver operating characteristic (ROC) analysis showed that SHR had the highest predictive performance for the outcome (area under the curve [AUC] = 0.611) compared with glycemic gap, admission glucose, and HbA1c. Conclusions: Relative hyperglycemia assessed by the SHR may be a more informative prognostic marker of mortality in critically ill patients with COVID-19 than chronic glycemic status reflected by HbA1c.
EUVIMED